Abstract Estrogen receptor-positive (ER+) breast cancer (BC) frequently metastasizes to bone, yet understanding how distinct bone compartments influence metastatic progression and
Preclinical in vitro and in vivo work demonstrating proof-of-concept for a novel engineered exosome delivery platform; lacks human clinical data, phase trials, or controlled comparator arms with reported effect sizes and statistical significance.